A Phase 3 interventional study of Glutamine and Standard of Care (SOC) in Sickle Cell Disease (SCD), sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Open to participants aged 1 Year to 5 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Ain Shams University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Anemia, Sickle Cell with a site in Egypt — 9 open to participants now, 10 under way, 3 of them phase 3. Anemia, Sickle Cell · Egypt.
Among the 33 studies in Anemia, Sickle Cell with a site in Egypt, this one is the 20th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 in phase 3, and was the 33rd registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →9 of the 33 studies in Anemia, Sickle Cell with a site in Egypt are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Egypt, United States, Canada and 14 more countries
Ages 2+
Cairo University · Sites in Egypt
Ages 20–50
Ain Shams University · Sites in Egypt
Ages up to 39
Adly A Adam · Sites in Egypt
Ages 9–14 · Healthy volunteers
Sohag University · Sites in Egypt
Ages 1–18 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 1 Year to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 13 · Phase 4 4
First in 2011; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 91 across the 29 interventional studies, 53 across the 4 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 33 have an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,956 studies on the registry; 431 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ain Shams University has 6 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
2 of the studies in Anemia, Sickle Cell with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07800247Ain Shams UniversityHemoglobin Disorders in Egypt: Sickle Cell Disease Ain Shams University Institutional Registry | 2027-01-01 |
| NCT07200869Assiut UniversityOutcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Anemia, Sickle Cell with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to assess the efficacy and safety of Glutamine in preventing Vaso Occlusive Crisis in pediatric population less than five years old
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Standard of Care (SOC)
Drug: Glutamine · Other: Standard of Care (SOC)
L-Glutamine as an oral powder
Standard of care in SCD therapy as Hydroxyurea
Assessment of safety of L-Glutamine in children with SCD younger than 5 years old
Assessment of safety of L-Glutamine in children with SCD younger than 5 years old by assessing the adverse event
Time frame: 52 weeks
Assessment of efficacy of L-Glutamine in reducing the occurrence of VOCs
Assessment of efficacy of L-Glutamine in reducing the occurrence of VOCs from baseline to week 52
Time frame: 52 weeks
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 35 phase 3 interventional studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 61. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.